{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:42:26Z","timestamp":1761745346686,"version":"3.37.3"},"reference-count":24,"publisher":"FapUNIFESP (SciELO)","issue":"suppl 2","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"abstract":"<jats:p>SUMMARY  OBJECTIVE  Coronavirus disease 2019 (COVID-19) is an emerging health threat caused by a novel coronavirus named severe acute respiratory syndrome coronavirus 2 (SARS-COV-2). Previous studies have noted hypertension is associated with increased mortality due to COVID-19; however, it is not clear whether the increased risk is due to hypertension itself or antihypertensive agents. We aimed to evaluate the impact of antihypertensive agents on the clinical outcomes of hypertensive patients with COVID-19.  METHODS  Our study included 169 consecutive hypertensive patients hospitalized due to COVID-19 between March 20 and April 10, 2020. The demographic characteristics, clinical data, and type of antihypertensive agents being used were reviewed.  RESULTS  The mean age of patients was 65.8\u00b111.7 years.30 patients(17.7%) died during hospitalization. A total of 142 patients(84%) were using angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs), 91 (53.8%) were using diuretics, 69 (40.8%) were using calcium channel blockers (CCBs), 66 (39.1%) were using beta-blockers, 12 (7.1%) were using alpha-blockers, and 5 (2.9%) were using mineralocorticoid receptor antagonists (MRAs). There was no significant difference between survivors and non-survivors based on the type of antihypertensive agents being used. Binary logistic regression analysis showed that the type of the antihypertensive agent being used had no effect on mortality [OR=0.527 (0.130-2.138), p=0.370 for ACEIs\/ARBs; OR=0.731 (0.296-1.808), p=0.498 for CCBs; OR=0.673 (0.254-1.782), p=0.425 for diuretics; OR=1.846 (0.688-4.950), p=0.223 for beta-blockers; OR=0.389 (0.089-1.695), p=0.208 for alpha-blockers; and OR=1.372 (0.107-17.639), p=0.808 for MRAs].  CONCLUSION  The type of antihypertensive agent being used had no effect on the clinical course and mortality in hypertensive patients with COVID-19. The use of these agents should be maintained for the treatment of hypertension during hospitalization.<\/jats:p>","DOI":"10.1590\/1806-9282.66.s2.71","type":"journal-article","created":{"date-parts":[[2020,9,21]],"date-time":"2020-09-21T19:41:39Z","timestamp":1600717299000},"page":"71-76","source":"Crossref","is-referenced-by-count":14,"title":["Impact of antihypertensive agents on clinical course and in-hospital mortality: analysis of 169 hypertensive patients hospitalized for COVID-19"],"prefix":"10.1590","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8295-9837","authenticated-orcid":false,"given":"Ibrahim","family":"Kocayigit","sequence":"first","affiliation":[{"name":"University of Sakarya,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8719-7031","authenticated-orcid":false,"given":"Havva","family":"Kocayigit","sequence":"additional","affiliation":[{"name":"Sakarya University,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6768-7973","authenticated-orcid":false,"given":"Selcuk","family":"Yaylaci","sequence":"additional","affiliation":[{"name":"University of Sakarya,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5325-4704","authenticated-orcid":false,"given":"Yusuf","family":"Can","sequence":"additional","affiliation":[{"name":"University of Sakarya,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6994-397X","authenticated-orcid":false,"given":"Ali Fuat","family":"Erdem","sequence":"additional","affiliation":[{"name":"University of Sakarya,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1514-1685","authenticated-orcid":false,"given":"Oguz","family":"Karabay","sequence":"additional","affiliation":[{"name":"University of Sakarya,  Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2020]]},"reference":[{"issue":"10229","key":"ref1","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","article-title":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","volume":"395","author":"Zhou F","year":"2020","journal-title":"Lancet"},{"key":"ref2","article-title":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","author":"Li J","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","author":"Meng J","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"12","key":"ref4","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","volume":"126","author":"Zhang P","year":"2020","journal-title":"Circ Res"},{"year":"2020","series-title":"Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020","key":"ref5"},{"issue":"5","key":"ref6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study","volume":"8","author":"Yang X","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"18","key":"ref7","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","volume":"382","author":"Guan WJ","year":"2020","journal-title":"N Engl J Med"},{"key":"ref8","article-title":"Is there an association between COVID-19 mortality and the renin-angiotensin system: a call for epidemiologic investigations","author":"Hanff TC","year":"2020","journal-title":"Clin Infect Dis"},{"key":"ref9","article-title":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?","author":"Patel AB","year":"2020","journal-title":"JAMA"},{"issue":"17","key":"ref10","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMsr2005760","article-title":"Renin angiotensin-aldosterone system inhibitors in patients with COVID-19","volume":"382","author":"Vaduganathan M","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"ref11","first-page":"525","article-title":"Data on prevalence of hypertension and blood pressure in Turkey: systematic review, meta-analysis and meta-regression of epidemiological studies on cardiovascular risk factors","volume":"46","author":"K\u0131l\u0131\u00e7kap M","year":"2018","journal-title":"Turk Kardiyol Dern Ars"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis","volume":"94","author":"Yang J","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"7","key":"ref13","article-title":"Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus","volume":"94","author":"Wan Y","year":"2020","journal-title":"J Virol"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(20)30116-8","article-title":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","volume":"8","author":"Fang L","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"3","key":"ref15","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1152\/physrev.00031.2016","article-title":"Role of the immune system in hypertension","volume":"97","author":"Rodriguez-Iturbe B","year":"2017","journal-title":"Physiol Rev"},{"issue":"5","key":"ref16","article-title":"Nifedipine and amlodipine are associated with improved mortality and decreased risk for intubation and mechanical ventilation in elderly patients hospitalized for COVID-19","volume":"12","author":"Solaimanzadeh I","year":"2020","journal-title":"Cureus"},{"issue":"5","key":"ref17","first-page":"963","article-title":"Nifedipine dilates the pulmonary vasculature without producing symptomatic systemic hypotension in upright resting and exercising patients with pulmonary hypertension secondary to chronic obstructive pulmonary disease","volume":"132","author":"Muramoto A","year":"1986","journal-title":"Am Rev Respir Dis"},{"issue":"2","key":"ref18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1136\/hrt.75.2.171","article-title":"Acute pulmonary vasodilatory properties of amlodipine in humans with pulmonary hypertension","volume":"75","author":"Woodmansey PA","year":"1996","journal-title":"Heart"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1378\/chest.111.6.1622","article-title":"A comparison of two long-acting vasoselective calcium antagonists in pulmonary hypertension secondary to COPD","volume":"111","author":"Sajkov D","year":"1997","journal-title":"Chest"},{"issue":"4","key":"ref20","first-page":"544","article-title":"Nifedipine inhibits hypoxic pulmonary vasoconstriction during rest and exercise in patients with chronic obstructive pulmonary disease: a controlled double-blind study","volume":"129","author":"Kennedy TP","year":"1984","journal-title":"Am Rev Respir Dis"},{"key":"ref21","article-title":"The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry in target cells","author":"Hoffmann M","year":"2020","journal-title":"BioRxiv"},{"issue":"10224","key":"ref22","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu R","year":"2020","journal-title":"Lancet"},{"issue":"9","key":"ref23","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1161\/01.RES.0000187500.24964.7A","article-title":"Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients","volume":"97","author":"Keidar S","year":"2005","journal-title":"Circ Res"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1161\/HYPERTENSIONAHA.109.138420","article-title":"Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension","volume":"55","author":"Wysocki J","year":"2010","journal-title":"Hypertension"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v66s2\/1806-9282-ramb-66-s2-071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,24]],"date-time":"2021-01-24T02:39:14Z","timestamp":1611455954000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302020001400071&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":24,"journal-issue":{"issue":"suppl 2","published-online":{"date-parts":[[2020]]}},"alternative-id":["S0104-42302020001400071"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.66.s2.71","relation":{},"ISSN":["1806-9282","0104-4230"],"issn-type":[{"type":"electronic","value":"1806-9282"},{"type":"print","value":"0104-4230"}],"subject":[],"published":{"date-parts":[[2020]]}}}